M2K Bio designs and deploys local Databricks-style Lakehouse AI architectures that unify data engineering, analytics, and machine learning into a single, high-performance platform—without the cost, vendor lock-in, or data-exposure risks of managed cloud services. These open, scalable systems give organizations full control over sensitive data while enabling reproducible AI workflows, enterprise-grade governance, and seamless integration with on-prem and HPC infrastructure.

Building on this foundation, M2K Bio applies advanced artificial intelligence and structural biophysics to revolutionize therapeutic biologic discovery. By leveraging generative deep learning and structure-guided design, we engineer high-affinity de novo miniproteins, VHH nanobodies, paired Fvs, and cyclic peptides tailored to exact target epitope hotspots. Our AI-driven pipelines dramatically accelerate discovery timelines compared to traditional approaches by delivering production-ready, stable, and developability-filtered binders optimized to minimize immunogenicity liabilities—enabling precision treatments for oncology, immunology, and infectious diseases. Request a custom design study here.

In summary, M2K Bio helps organizations: design and deploy local Lakehouse AI architectures; design and optimize antibodies for targeted therapies; and analyze diverse omics data to drive faster, more effective biomedical innovation.